France just got a quantitative accounting of what 809 autochthonous chikungunya cases really cost, and the paper lands while Mainland EU autochthonous dengue and chikungunya stays at zero through Q2 close

There is a peculiar arithmetic to a zero. While it holds, it looks like nothing is happening. The moment it breaks, the question stops being whether autochthonous arbovirus transmission is possible in Mainland Europe and becomes how much it costs when it does.

That arithmetic now has a ledger.

A study in IJID Regions, From bites to ripple effects: Unraveling the health, economic, and social effects of arboviral epidemics in Mainland France (PMID 42382010, ahead of print Sep 2026), has set out the first quantitative cost-of-illness accounting for a single arboviral season in metropolitan France. It lands in the same week that the European Centre for Disease Prevention and Control W25 monthly is on record confirming no autochthonous dengue or chikungunya cases in the EU/EEA outside the outermost regions, with the W27 report pending. The Mainland EU autochthonous counter has stayed at zero through Q2 close.

What we know

• Santé publique France's Bilan 2025 published 6 May 2026 records 809 autochthonous chikungunya cases and 30 autochthonous dengue cases in metropolitan France, the highest chikungunya year since surveillance began in 2006.
• The ECDC W25 monthly confirms no autochthonous dengue or chikungunya cases in the EU/EEA outside the outermost regions, with W27 pending.
• The IJID Regions paper (PMID 42382010) is the first 2026 cost-of-illness accounting for Mainland France arboviral epidemics, with health-system, economic and social ripple effects in a single frame.
• A retrospective German statutory health insurance dengue burden assessment covering 2014 to 2023 (J Travel Med 30 June 2026, PMID 42275075) lays out the same ledger structure for a second non-endemic country.
• A prospective cohort of travellers returning from Paraguay with chikungunya (J Travel Med 30 June 2026, PMID 42231566) documents the long-tail clinical consequences that headline totals systematically miss.

The paper that changed the headline

France's 2025 autochthonous wave was already on the public-health record. What the IJID Regions paper adds is the cost record. Health-system costs from clinical and outpatient care, economic costs from presenteeism and lost workdays and informal caregiving, and social costs from quality-of-life loss and household disruption are now written into a single cost-of-illness frame, paired with a structural argument that the figure underestimates the true burden because non-endemic countries systematically underdiagnose and underreport.

That last point matters more than the number itself. A zero in the Mainland EU autochthonous counter is fragile, and any cost accounting built on the assumption that the zero holds will understate the consequences of the moment it breaks. The 809-and-30 total is therefore best read as the floor, not the ceiling, of what a single autochthonous season in a non-endemic country actually imposes.

Two non-endemic countries, one direction of travel

The French paper does not stand alone. On 30 June 2026 a separate German study in J Travel Medicine ran a retrospective statutory health insurance analysis covering 2014 to 2023. Its conclusion was that Germany's documented dengue burden is a fraction of what is likely present in clinical reality. The institutional ledger systematically undercounts because most cases never reach a coded diagnosis in a country where dengue is not on the clinician's reflex radar.

Italy contributes two more pieces of the same picture. Stefanizzi et al. (Front Public Health 2026, PMID 42180454) work through the climate-change implications of autochthonous chikungunya re-emergence; Buonfrate et al. (J Infect 2026, PMID 41845966) document the burden imposed by Verona's 2025 autochthonous summer. Over in French Guiana (outside the Mainland EU frame, but on the regional periphery of the editorial picture), Sinturel MP et al. (Euro Surveill 2026, PMID 42170750) and the SpF Guyane S25 bulletin describe a cumulative 916-case chikungunya season still working through.

Same direction. Different countries. Different arboviruses. Different years. The single thing they share is a structural under-recognition in country-level public-health ledgers.

The protection layer that exists now

While the institutional cost accounting matures, the protection layer available in the present has not changed. WHO-aligned guidance in non-endemic countries still rests on three pillars: physical barriers (long-sleeved clothing, treated or untreated mosquito nets, window and door screening), repellents applied according to label, and source reduction around households, including emptied containers, cleared gutters and kept-dry standing water. For treated nets that include a permethrin-treated layer, the relevant regulatory frame is the European Biocidal Products Regulation (BPR); treated products are not blanket-recommended for all populations, and any recommendation should match local label scope and population need.

A consistent theme across recent adaptation research, including Delor et al. in Int J Infect Dis 2026 (PMID 42218977), is that individual risk perception and household practice lag behind the structural drivers of autochthonous transmission: rising mean temperatures, the spread of Aedes albopictus north and west across Europe, and globalised trade routes that move container habitat across borders. The climate-and-trade layer is now the most reproducible predictor in the ensemble models (Zhang Q et al., Front Cell Infect Microbiol 2026, PMID 42282277), and the human adaptation layer remains the weakest.

The companion vaccine-mechanism paper this week, Kim YC et al., Npj Viruses 30 June 2026 (PMID 42380244), on ChAdOx1 chikungunya-derived VLP immunogenic characterisation, sits squarely in third-party research. It is a structural result about how a particular vaccine platform presents chikungunya antigens; it is not an endorsement, criticism, or operational recommendation for any deployed vaccine programme. Mosticare does not make vaccine claims and does not run vaccine programmes; we note the research as part of the wider European mosquito-borne picture and leave the vaccine-mechanism layer to the agencies whose remit it is.

What the zero buys, and what it doesn't

Mainland EU autochthonous dengue and chikungunya holding at zero through Q2 close is a structural good, not a permanent one. The ECDC W26 West Nile virus weekly (Italy Caserta, Italy Firenze, North Macedonia Vardarski, three cases across two countries and three areas) confirms that mosquito-borne transmission in Europe is a moving target even when the headline zero holds.

The shape of the next twelve months will be set less by whether a single season breaks the zero and more by whether the institutional cost ledgers now being built on those breakout seasons move European policy from reactive response to proactive, climate-aligned prevention. The IJID Regions paper, the German SHI analysis, and the Italian climate-and-burden papers now make that conversation harder to defer.

Until the prevention layer institutionalises, the protection layer in your house and on your skin tonight is the one you can act on.

Sources

• Santé publique France. Bilan 2025 arboviroses en métropole. Published 6 May 2026.
• European Centre for Disease Prevention and Control. W25 dengue monthly; W26 West Nile virus weekly (data 24 June 2026).
• Apouey B et al. From bites to ripple effects: Unraveling the health, economic, and social effects of arboviral epidemics in Mainland France. IJID Regions 2026 (ahead of print, Sep). PMID 42382010.
• Lübbert C et al. J Travel Med 2026 Jun 30. Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-23). PMID 42275075.
• de la Calle-Prieto F et al. J Travel Med 2026 Jun 30. Beyond a mild viral illness: long-term consequences in travellers with chikungunya from Paraguay. PMID 42231566.
• Kim YC et al. Npj Viruses 2026 Jun 30. ChAdOx1 chikungunya-derived VLP structural and immunogenic characterisation. PMID 42380244.
• Stefanizzi P et al. Front Public Health 2026. PMID 42180454.
• Buonfrate D et al. J Infect 2026. PMID 41845966.
• Sinturel MP et al. Euro Surveill 2026. PMID 42170750.
• Delor E et al. Int J Infect Dis 2026. PMID 42218977.
• Zhang Q et al. Front Cell Infect Microbiol 2026. PMID 42282277.

Published 2026-07-02 · Mosticare Editorial